Wednesday, July 8, 2026

pharma · Epilepsy · Allergic Reaction · AQST

Aquestive Therapeutics

Aquestive Therapeutics patent portfolio — 17 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

Vancouver, CA HQ
2009 Founded
75 Employees
Public company Type
AQST · NYSE Ticker
Company details
Status
Public
HQ
Vancouver, CA
Founded
2009
Employees
75
Programs
9
Drugs
9
Patents
17
Intelligence · Patents

Aquestive Therapeutics patents

17 pharmaceutical patents indexed for Aquestive Therapeutics. 0 expire within 24 months.

Aquestive Therapeutics has 17 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

Patent portfolio

  1. US 12427121

    Enhanced delivery epinephrine compositions

    Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. US 12403090

    Oral film compositions and dosage forms having precise active dissolution profiles

    Expires Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  3. US 12290597

    Oral film compositions and dosage forms having precise active dissolution profiles

    Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  4. US 12023309

    Enhanced delivery epinephrine compositions

    Expires Mon Jun 27 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  5. US 11541002

    Oral film compositions and dosage forms having precise active dissolution profiles

    Expires Mon Dec 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  6. US 11273131

    Pharmaceutical compositions with enhanced permeation

    Expires Mon Mar 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  7. US 11191737

    Enhanced delivery epinephrine compositions

    Expires Mon Dec 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  8. US 11129799

    Dual lane coating

    Expires Mon Sep 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  9. US 11077068

    Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions

    Expires Mon Jul 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  10. US 10947033

    Reduction in stress cracking of films

    Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  11. US 10940626

    Manufacturing of small film strips

    Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  12. US 10888499

    Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom

    Expires Mon Jan 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  13. US 10821074

    Sublingual and buccal film compositions

    Expires Mon Oct 29 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  14. US 10464739

    Reduction in stress cracking of films

    Expires Mon Oct 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  15. US 10272607

    Manufacturing of small film strips

    Expires Mon Apr 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  16. US 10111810

    Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom

    Expires Mon Oct 25 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  17. US 10034833

    Sublingual and buccal film compositions

    Expires Mon Jul 26 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Aquestive Therapeutics have?

17 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Aquestive Therapeutics patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.